Cancer recurrence and survival rates after anatomic radical retropubic prostatectomy for prostate cancer: intermediate-term results. J Urol. 1998; 160 :2428–2434. [ PubMed ]Catalona WJ, Smith DS. Cancer recurrence and survival rates after anatomic radical retropubic prostatectomy for prostate cancer:...
Carbamidomethyl (C) and 13CD3 (M) (4.0222 Da) were set as fixed modification, Acetyl (Protein N-term), 13CD3+Oxidation (M) (20.0717 Da), 13CD3-methylation (K) (18.0378 Da), 13CD3-dimethylation (K) (36.0757 Da) and 13CD3-trimethylation (K) (54.1135 Da) were set as variable ...
PCa is the third most common cause of cancer-associated death in men worldwide and progression is unpredictable [7]. Patients with similar tumour grade and histology can quickly progress to incurable, advanced metastatic disease or alternatively they can survive for decades with local, indolent, dis...
The treatment period is one month. Most long term chronic prostatitis is healed in 1-2 rounds (or months). The PSA level will go down in 1 round. Enlarged prostate will shrink in 2-3 rounds. Prostate cancer needs 3-4 rounds to recover a normal test. Even after stopping the medicines ...
D. et al. Medium-term outcomes of active surveillance for localised prostate cancer. Eur. Urol. 64, 981–987 (2013). PubMed Google Scholar Soloway, M. S. et al. Careful selection and close monitoring of low-risk prostate cancer patients on active surveillance minimizes the need for ...
Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial. Lancet 2002; 360: 103–106. Article CAS Google Scholar Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, ...
Limited data are available concerning long-term prostate cancer (PCa)-related medical costs for use in assessing PCa prevention strategies. The aim of this study was to examine treatment, long-term survival, and long-term PCa-related costs by cancer stage. Costs in phases of care based on the...
Screening for prostate cancer: US Preventive Services Task Force recommendation statement. Ann Intern Med. 2012;157(2):120-134.PubMedGoogle ScholarCrossref 4. Pinsky PF, Prorok PC, Kramer BS. Prostate cancer screening—a perspective on the current state of the evidence. N...
Mortality results from the Göteborg randomised population-based prostate-cancer screening trial Lancet Oncol (2010) M. Bolla et al. External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomised study Lancet ...
Selvadurai ED, Singhera M, Thomas K, Mohammed K, Woode-Amissah R, Horwich A, Huddart RA, Dearnaley DP, Parker CC (2013) Medium-term outcomes of active surveillance for localised prostate cancer. Eur Urol 64: 981–987. Soloway MS, Soloway CT, Eldefrawy A, Acosta K, Kava B, ...